Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479777/606-10-55-91

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479428/808-10-45-3

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Segment Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue
Total net revenues	$ 13,927	$ 14,812	$ 40,017	$ 42,933
All other
Disaggregation of Revenue
Net revenues	782	925	2,214	3,145
Immunology \| Humira
Disaggregation of Revenue
Net revenues	3,547	5,559	11,100	15,658
Immunology \| Humira \| United States
Disaggregation of Revenue
Net revenues	3,020	4,956	9,420	13,613
Immunology \| Humira \| International
Disaggregation of Revenue
Net revenues	527	603	1,680	2,045
Immunology \| Skyrizi
Disaggregation of Revenue
Net revenues	2,126	1,397	5,369	3,589
Immunology \| Skyrizi \| United States
Disaggregation of Revenue
Net revenues	1,875	1,221	4,648	3,081
Immunology \| Skyrizi \| International
Disaggregation of Revenue
Net revenues	251	176	721	508
Immunology \| Rinvoq
Disaggregation of Revenue
Net revenues	1,110	695	2,714	1,752
Immunology \| Rinvoq \| United States
Disaggregation of Revenue
Net revenues	801	505	1,895	1,228
Immunology \| Rinvoq \| International
Disaggregation of Revenue
Net revenues	309	190	819	524
Hematologic Oncology \| Imbruvica
Disaggregation of Revenue
Net revenues	908	1,135	2,693	3,453
Hematologic Oncology \| Imbruvica \| United States
Disaggregation of Revenue
Net revenues	678	849	1,982	2,585
Hematologic Oncology \| Imbruvica \| International
Disaggregation of Revenue
Collaboration revenues	230	286	711	868
Hematologic Oncology \| Venclexta
Disaggregation of Revenue
Net revenues	590	515	1,699	1,493
Hematologic Oncology \| Venclexta \| United States
Disaggregation of Revenue
Net revenues	281	259	811	740
Hematologic Oncology \| Venclexta \| International
Disaggregation of Revenue
Net revenues	309	256	888	753
Hematologic Oncology \| Epkinly
Disaggregation of Revenue
Collaboration revenues	14	0	14	0
Aesthetics \| Botox Cosmetic
Disaggregation of Revenue
Net revenues	620	637	1,964	1,973
Aesthetics \| Botox Cosmetic \| United States
Disaggregation of Revenue
Net revenues	388	370	1,217	1,232
Aesthetics \| Botox Cosmetic \| International
Disaggregation of Revenue
Net revenues	232	267	747	741
Aesthetics \| Juvederm Collection
Disaggregation of Revenue
Net revenues	321	352	1,044	1,106
Aesthetics \| Juvederm Collection \| United States
Disaggregation of Revenue
Net revenues	116	125	363	420
Aesthetics \| Juvederm Collection \| International
Disaggregation of Revenue
Net revenues	205	227	681	686
Aesthetics \| Other Aesthetics
Disaggregation of Revenue
Net revenues	298	312	915	967
Aesthetics \| Other Aesthetics \| United States
Disaggregation of Revenue
Net revenues	255	265	785	837
Aesthetics \| Other Aesthetics \| International
Disaggregation of Revenue
Net revenues	43	47	130	130
Neuroscience \| Botox Therapeutic
Disaggregation of Revenue
Net revenues	748	699	2,215	1,991
Neuroscience \| Botox Therapeutic \| United States
Disaggregation of Revenue
Net revenues	626	584	1,827	1,641
Neuroscience \| Botox Therapeutic \| International
Disaggregation of Revenue
Net revenues	122	115	388	350
Neuroscience \| Vraylar
Disaggregation of Revenue
Net revenues	751	554	1,970	1,473
Neuroscience \| Vraylar \| United States
Disaggregation of Revenue
Net revenues	750	554	1,967	1,473
Neuroscience \| Vraylar \| International
Disaggregation of Revenue
Net revenues	1	0	3	0
Neuroscience \| Duodopa
Disaggregation of Revenue
Net revenues	118	110	353	351
Neuroscience \| Duodopa \| United States
Disaggregation of Revenue
Net revenues	25	22	74	72
Neuroscience \| Duodopa \| International
Disaggregation of Revenue
Net revenues	93	88	279	279
Neuroscience \| Ubrelvy
Disaggregation of Revenue
Net revenues	233	160	581	483
Neuroscience \| Ubrelvy \| United States
Disaggregation of Revenue
Net revenues	230	160	574	483
Neuroscience \| Ubrelvy \| International
Disaggregation of Revenue
Net revenues	3	0	7	0
Neuroscience \| Qulipta
Disaggregation of Revenue
Net revenues	132	62	294	106
Neuroscience \| Qulipta \| United States
Disaggregation of Revenue
Net revenues	131	62	292	106
Neuroscience \| Qulipta \| International
Disaggregation of Revenue
Net revenues	1	0	2	0
Neuroscience \| Other Neuroscience
Disaggregation of Revenue
Net revenues	61	87	210	414
Neuroscience \| Other Neuroscience \| United States
Disaggregation of Revenue
Net revenues	55	82	195	400
Neuroscience \| Other Neuroscience \| International
Disaggregation of Revenue
Net revenues	6	5	15	14
Eye Care \| Ozurdex
Disaggregation of Revenue
Net revenues	120	106	354	323
Eye Care \| Ozurdex \| United States
Disaggregation of Revenue
Net revenues	34	35	107	104
Eye Care \| Ozurdex \| International
Disaggregation of Revenue
Net revenues	86	71	247	219
Eye Care \| Lumigan/Ganfort
Disaggregation of Revenue
Net revenues	91	121	340	391
Eye Care \| Lumigan/Ganfort \| United States
Disaggregation of Revenue
Net revenues	28	59	142	186
Eye Care \| Lumigan/Ganfort \| International
Disaggregation of Revenue
Net revenues	63	62	198	205
Eye Care \| Alphagan/Combigan
Disaggregation of Revenue
Net revenues	70	73	206	272
Eye Care \| Alphagan/Combigan \| United States
Disaggregation of Revenue
Net revenues	30	37	90	161
Eye Care \| Alphagan/Combigan \| International
Disaggregation of Revenue
Net revenues	40	36	116	111
Eye Care \| Restasis
Disaggregation of Revenue
Net revenues	117	142	308	556
Eye Care \| Restasis \| United States
Disaggregation of Revenue
Net revenues	104	132	265	518
Eye Care \| Restasis \| International
Disaggregation of Revenue
Net revenues	13	10	43	38
Eye Care \| Other Eye Care
Disaggregation of Revenue
Net revenues	207	181	622	569
Eye Care \| Other Eye Care \| United States
Disaggregation of Revenue
Net revenues	114	99	334	296
Eye Care \| Other Eye Care \| International
Disaggregation of Revenue
Net revenues	93	82	288	273
Other Key Products \| Mavyret
Disaggregation of Revenue
Net revenues	370	383	1,121	1,161
Other Key Products \| Mavyret \| United States
Disaggregation of Revenue
Net revenues	167	190	531	562
Other Key Products \| Mavyret \| International
Disaggregation of Revenue
Net revenues	203	193	590	599
Other Key Products \| Creon \| United States
Disaggregation of Revenue
Net revenues	305	336	892	941
Other Key Products \| Linzess/Constella
Disaggregation of Revenue
Net revenues	288	271	825	766
Other Key Products \| Linzess/Constella \| United States
Disaggregation of Revenue
Net revenues	279	262	799	742
Other Key Products \| Linzess/Constella \| International
Disaggregation of Revenue
Net revenues	$ 9	$ 9	$ 26	$ 24